MoonLake Immunotherapeutics MLTX
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 87th percentile, 5-year average -26.0x
Near the bottom of its 5-year range · 19th percentile, 5-year average 6.9x
#3637 of 5329 stocks by PB (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.79 | – | 6.86 | 19% (cheaper than usual) | #3637 of 5329 (1 = cheapest) |
| PE | -3.42 | -3.37 | -26.04 | 87% (pricier than usual) | – |
| PS | – | 1,180.20 | 0.00 | – | – |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on MLTX.
Sign in to join the discussion.